Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer

Bookmark and Share
Published: 9 Jun 2015
Views: 2762
Rating:
Save
Dr Simon Chowdhury - Guy's Hospital, London, UK

Dr Chowdhury talks to ecancertv at ASCO 2015 about the results of the TERRAIN study which looked at the use of 160 mg of enzalutamide taken orally once daily versus bicalutamide at a dose of 50mg taken once daily in combination with an LHRH analogue in patients with metastatic prostate cancer whose disease had progressed despite treatment with luteinizing hormone-releasing hormone (LHRH) analogue therapy or surgical castration.

Results showed median progression free survival was 15.7 months in the enzalutamide arm compared to 5.8 months in the bicalutamide plus LHRH analogue arm (HR 0.44, 95% CI 0.34-0.57; p<0.0001).

Please see the news story for more.

He also comments on the STAMPEDE trial, which found that adding docetaxel chemotherapy to standard hormone therapy markedly improved survival for men with newly diagnosed advanced prostate cancer not previously treated with hormone therapy (hormone- naïve).

See the news story for more.